# Chai Discovery

> Chai Discovery is a San Francisco AI biotechnology company that builds molecular structure and design models for drug researchers. Its open Chai-1 model predicts biomolecular structures; its controlled-access Chai-2 and Chai-3 tools help pharmaceutical and biotech teams design antibodies and other protein binders against specified targets. Its published Chai-2 experiments reported a 16% antibody binding hit rate across 52 targets, while its commercial partnerships put the models into drug-discovery workflows.

- **Founded:** 2024
- **Headquarters:** San Francisco, United States
- **Founders:** Joshua Meier (Co-founder and CEO), Jack Dent (Co-founder and President), Matthew McPartlon (Co-founder and CTO), Jacques Boitreaud (Co-founder)
- **Products:** Chai-1, Chai-2, Chai-3, Chai platform
- **Notable:** Chai-1 released with free commercial web access and Apache 2.0 code and weights in 2024., Chai-2 reported 16% binding across an initial set of de novo antibody designs for 52 targets, with at least one binder for 50% of targets tested with no more than 20 designs each., A later Chai-2 study reported that 86% of 88 designed full-length IgGs had zero or one flagged developability issue.

## Products & services

- **Chai-1** — Open, multimodal molecular structure prediction model and free web interface; code and weights released under Apache 2.0.
- **Chai-2** — Controlled-access generative design models for antibodies, nanobodies and miniproteins against chosen targets and epitopes.
- **Chai-3** — Next-generation molecular design model available through enterprise platform partnerships; company reports stronger binding, multispecific design and performance on difficult targets.
- **Chai platform** — Software workflow for specifying target, antibody format, epitope and design constraints, with commercial access by arrangement.

## Achievements

- Chai-1 released with free commercial web access and Apache 2.0 code and weights in 2024.
- Chai-2 reported 16% binding across an initial set of de novo antibody designs for 52 targets, with at least one binder for 50% of targets tested with no more than 20 designs each.
- A later Chai-2 study reported that 86% of 88 designed full-length IgGs had zero or one flagged developability issue.
- Chai reported antibody binders for all six GPCR targets it tested in a later study.
- July 2026 Series C raised $400 million at a stated $3.8 billion valuation.

## Latest updates

- **2026-08** — Announced a therapeutic antibody discovery collaboration with Bristol Myers Squibb.
- **2026-07** — Announced an argenx collaboration, a Novartis collaboration and a $400 million Series C at a $3.8 billion valuation.
- **2026-06** — Announced a Pfizer license agreement and a second Lilly arrangement through TuneLab.
- **2025-11** — Published Chai-2 work on full-length antibodies, developability and hard-to-drug targets.

## Links

- Website: https://www.chaidiscovery.com/
- LinkedIn: https://www.linkedin.com/company/chaidiscovery/
- Twitter/X: https://x.com/chaidiscovery
- GitHub: https://github.com/chaidiscovery

---

Profile page: https://yespress.io/chai-discovery
Published by YesPress — https://yespress.io
Last updated: 2026-09-29